alexa
Reach Us +1-947-333-4405

GET THE APP

Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Predictors Of Response To Methotrexate In Juvenile Idiopathic Arthritis | 45257
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1300

Journal of Clinical & Experimental Pathology received 1300 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Predictors of response to methotrexate in juvenile idiopathic arthritis

6th European Pathology Congress

Mohamed Albarouni

Bonn University, Germany

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.C1.022

Abstract
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic illness in children and it is responsible for short and long-term disability. In the recent years an increased number of disease-modifying anti-rheumatic drugs (DMARDs) have been developed for treatment of juvenile idiopathic arthritis, but methotrexate still the most common second line therapeutic agent used in treatment of JIA worldwide, either as mono-therapy or in combination with biologic agents. However, there is variation in the clinical response to methotrexate among the patients. The main goal of juvenile idiopathic arthritis treatment is the achievement of wellbeing with minimal risk of side effects. Prediction of response can prevent further exposing of patients to side effects of methotrexate and also saving the time by progressing to the treatment with an alternative therapy (e.g. biological drugs) as soon as possible to prevent irreversible complications. Identification of predictors of response might also be helpful to develop recommendations for methotrexate use, especially starting of methotrexate as well as further continuation or early discontinuation and starting use of an alternative therapy. The aim of this study is to determine whether demographic, clinical, articular and laboratory variables at baseline predict methotrexate response in patients with juvenile idiopathic arthritis.
Biography

Mohamed Albarouni is working as a Pediatrician since 2007. He has completed his MBBCh from Tripoli University in Libya. He earned his MD degree from University of Bonn in Germany. From 2010-2014, he worked in the Centre of Pediatric Rheumatology in Asklepios Clinic Sankt Augustin, Germany. In 2014, he has won the Poster Award of the German Society for Pediatric Rheumatology. Since 2015, he has been working in the Department of Pediatrics in St. Elisabeth Hospital in Wittlich, Germany.

Email: [email protected]

Top